Clinical Case Discussion Forum

Subscribe to the Clinical Case Discussion Forum

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Giving G-CSF in CML

Ehab Atallah
Topic Author

1 month 2 weeks ago - 3 weeks 1 day ago #2049 by Ehab Atallah

Giving G-CSF in CML was created by Ehab Atallah

53 year old female diagnosed with CP-CML (WBC: 200,000 and Hb 8) and stage II breast cancer at same time.
Standard treatment: Dose dense Neoadjuvant AC/T followed by surgery followed by hormonal.

Given high count: Plan: Imatinib-->Surgery-->Dose dense ACT with G-CSF. Continue imatinib through all treatment. Consider switching to dasatinib after completion of therapy.

Thoughts?

Last edit: 3 weeks 1 day ago by arlene.

Gianantonio Rosti
Topic Author

2 weeks 6 days ago #2074 by Gianantonio Rosti

Replied by Gianantonio Rosti on topic Giving G-CSF in CML

The published experience is scarce. I like the plan: imatinib (ELTS RISK?) to complete and stable hematological response (when the risk of subsequent cytopenia is perceived to be reduced to ‘zero’’) followed by surgery > dose dense ACT.

Imatinib continued? Yes, in my past experience continuing imatinib during CHT was generally free of additional safety and clinical issues - I remember at least 3 cases similar to the present one.

Switching to Dasatinib at the end of treatment: I would consider this only if the response to and tolerability of imatinib are not optimal. Dasatinib is (considered) a strong immune-suppressant drug - acknowledged, more in vitro than proved in vivo - and knowing the relevance of immune response in breast cancer, an additional discussion point at the time of switching will be considered.

Hope this comment will contribute to finalize / improve the case discussion.

Valentin Garcia Gutierrez
Topic Author

2 weeks 6 days ago #2075 by Valentin Garcia Gutierrez

Replied by Valentin Garcia Gutierrez on topic Giving G-CSF in CML

In this situation, I would personally wait to see how the patient tolerates the first cycle of chemotherapy before starting the TKI. I would consider initiating the TKI after recovery from the nadir of the first cycle.

Mhairi Copland
Topic Author

2 weeks 6 days ago #2076 by Mhairi Copland

Replied by Mhairi Copland on topic Giving G-CSF in CML

This is not an unusual situation in clinical practice. It would be hoped that both malignancies are associated with normal or near normal life span if optimal treatment and response are achieved. It would be useful to know the grade of the breast cancer. I note it is hormone sensitive. I think I would defer the Neo-adjuvant ACT until WCC <20, with Imatinib and then commence the ACT with Epo and G-CSF support as required. I would try to maintain Imatinib therapy throughout, but it may be the patient requires a reduced dose. I would interrupt imatinib therapy at the time of surgery for 7-10 days to optimise wound healing (length dependent on blood counts as well as extent of surgery). I wouldn't switch to dasatinib unless patient was failing on Imatinib and they had received adequate Imatinib therapy during the breast cancer treatment.

Nicholas Anthony Othieno-Abinya
Topic Author

2 weeks 6 days ago #2077 by Nicholas Anthony Othieno-Abinya

Replied by Nicholas Anthony Othieno-Abinya on topic Giving G-CSF in CML

This is a situation we have encountered in patients who develop breast cancer in the course of CML treatment. At the initiation of breast cancer chemotherapy we discontinue TKI s since peripheral blood counts tend to remain stable.
We administer prophlyactic G-CSF as required to avoid severeneutropenia(G4) and encounter no problems. After completion of chemotherapy we resume TKIs.

Delphine Rea
Topic Author

2 weeks 5 days ago #2078 by Delphine Rea

Replied by Delphine Rea on topic Giving G-CSF in CML

TKI needed in parallel to neoadjuvant CT as CT alone might not be sufficient to induce a CHR and is not going to trigger an EMR.

I would use the TKI with lowest risk of cytopenia and non hematologic AE, in my opinion ASCIMINIb 1st line would be best, full dose (if no e3 transcript).
Any idea of Karyotype and ELTS?

I would try to maintain TKI full dose until MR2/MMR with indeed, hematopoietic growth factors/supportive care whenever needed and to interrupt/dose reduce TKI only of jeopardizing optimal breast cancer therapy or safety.

Moderators: Nicola, arlene

Copyright © 2023 All Rights Reserved. The iCMLf is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK